Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 50
Filtrar
1.
Br J Dermatol ; 182(5): 1194-1204, 2020 05.
Artigo em Inglês | MEDLINE | ID: mdl-31370093

RESUMO

BACKGROUND: Acantholysis in pemphigus vulgaris (PV) may be triggered by desmoglein (Dsg) and non-Dsg autoantibodies. The autoantibody profile of each patient results in distinct intracellular signalling patterns. OBJECTIVES: Based on our previous findings, we aimed to elucidate whether PV acantholysis in a mouse model may be mediated by activation of a disintegrin and metalloproteinase 10 (ADAM10). METHODS: We used three PV-IgG fractions from different patients containing high or low levels of anti-Dsg1 and anti-Dsg3 antibodies, and the presence or not of anti-desmocollin (Dsc) antibodies, using a passive transfer mouse model of PV. RESULTS: Although all of the PV-IgG fractions produced suprabasal acantholysis, only those containing anti-Dsg1/3, but not anti-Dsc2/3 antibodies, induced ADAM10 activation in a Src-dependent way, and an increase in the epidermal growth factor (EGF) receptor ligands EGF and betacellulin (BTC). In contrast, the presence of anti-Dsc2/3 antibodies, in addition to anti-Dsg1/3, triggered earlier and ADAM10-independent epidermal detachment, with no increase in EGF and BTC, which was associated with an earlier and more intense acantholysis. CONCLUSIONS: All PV-IgG fractions produced suprabasal acantholysis, but our results reveal that depending on the levels of anti-Dsg antibodies or the presence of non-Dsg antibodies, such as anti-Dsc, more severe cell-cell epidermal detachment will occur at different times, and in an ADAM10-dependent manner or not. Acantholysis in these different groups of patients with PV may be a consequence of the activation of specific intracellular mechanisms downstream of Autoantibodies binding to Dsg or non-Dsg proteins, and therefore more specific therapeutic approaches in PV should be used. What's already known about this topic? Suprabasal acantholysis in pemphigus vulgaris (PV) may be triggered by both desmoglein (Dsg) and non-Dsg autoantibodies. The autoantibody profile of each patient is associated with a distinct intracellular signalling pattern. What does this study add? In patients with PV with anti-Dsg3 and anti-Dsg1, but not anti-desmocollin (Dsc)3 antibodies, ADAM10 activation is induced in an Src-dependent way, together with an increase in the epidermal growth factor receptor (EGFR) ligands EGF and betacellulin. The presence of anti-Dsc3 antibodies triggers an earlier and ADAM10-independent acantholysis, without increasing EGFR ligands, and is associated with more severe epidermal detachment. Lower levels of anti-Dsc3 antibodies are associated with less severe acantholysis. What is the translational message? In some patients with PV, the severity and the timing for cell-cell detachment seem to depend on the level of anti-Dsg1/3 antibodies, although other as yet uncharacterized antibodies may also participate. These patients with PV would exhibit inhibition of acantholysis by Src, ADAM10, EGF and EGFR inhibitors. In other patients, the presence of non-Dsg antibodies, such as anti-Dsc2/3, would produce an earlier and more severe ADAM10-independent suprabasal acantholysis.


Assuntos
Acantólise , Autoanticorpos , Pênfigo , Proteína ADAM10 , Secretases da Proteína Precursora do Amiloide , Animais , Desmogleína 1 , Desmogleína 3 , Humanos , Proteínas de Membrana , Camundongos
2.
Gene Ther ; 23(10): 753-759, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27416077

RESUMO

Immune responses against multiple epitopes are required for the prevention of hepatitis C virus (HCV) infection, and the progression to phase I trials of candidates may be guided by comparative immunogenicity studies in non-human primates. Four vectors, DNA, SFV, human serotype 5 adenovirus (HuAd5) and Modified Vaccinia Ankara (MVA) poxvirus, all expressing hepatitis C virus Core, E1, E2 and NS3, were combined in three prime-boost regimen, and their ability to elicit immune responses against HCV antigens in rhesus macaques was explored and compared. All combinations induced specific T-cell immune responses, including high IFN-γ production. The group immunized with the SFV+MVA regimen elicited higher E2-specific responses as compared with the two other modalities, while animals receiving HuAd5 injections elicited lower IL-4 responses as compared with those receiving MVA. The IFN-γ responses to NS3 were remarkably similar between groups. Only the adenovirus induced envelope-specific antibody responses, but these failed to show neutralizing activity. Therefore, the two novel regimens failed to induce superior responses as compared with already existing HCV vaccine candidates. Differences were found in response to envelope proteins, but the relevance of these remain uncertain given the surprisingly poor correlation with immunogenicity data in chimpanzees, underlining the difficulty to predict efficacy from immunology studies.


Assuntos
Linfócitos B/imunologia , Epitopos/genética , Hepacivirus/imunologia , Linfócitos T/imunologia , Vacinas contra Hepatite Viral/imunologia , Adenoviridae/genética , Animais , Linhagem Celular , Cricetinae , Epitopos/imunologia , Vetores Genéticos/genética , Imunogenicidade da Vacina , Interferon gama/sangue , Interleucina-4/sangue , Macaca mulatta , Masculino , Vaccinia virus/genética , Vacinas contra Hepatite Viral/genética
3.
Scand J Immunol ; 69(2): 80-9, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19144076

RESUMO

The development of immunization strategies to induce strong and multiepitopic T-cell responses against tumour antigens is needed for anti-tumour immunotherapy. However, a common finding after immunization with complex antigens is the preferential induction of immune responses against immunodominant epitopes. In this study, with the aim of inducing multiepitopic responses against several common tumour antigens, we have designed a minigene construct encoding four human leucocyte antigen (HLA)-A2-restricted epitopes belonging to tumour antigens CEA (CEA-691 and CEA-571), MAGE2 (MAGE2-157) and MAGE3 (MAGE3-112), as well as the universal PADRE epitope recognized by T helper lymphocytes. To optimize the activation of immune responses against these epitopes, we have used different antigen formats (short peptides encompassing individual epitopes and DNA plasmids or adenoviral constructs expressing the minigene) in single or combined immunization schedules. A single immunization with either DNA plasmid or recombinant adenovirus induced a monospecific immune response against the immunodominant epitope CEA-571, whereas immunization with the peptide pool induced responses against all epitopes. Combination of peptide priming followed by a boost with the plasmid and the recombinant adenovirus expressing the minigene induced stronger, multi-specific and long-lasting immune responses, overcoming the immunodominance imposed by the main T-cell epitope. Moreover, these combined immunization strategies were able to induce responses that were able to recognize Mel624 HLA-A2+ tumour cells expressing MAGE2. These results suggest that heterologous immunization strategies combining peptides and DNA or recombinant adenoviruses can be useful to broaden the specificity and enhance the efficacy of subunit vaccines.


Assuntos
Antígenos de Neoplasias/imunologia , Vacinas Anticâncer/imunologia , Epitopos de Linfócito T , Peptídeos/imunologia , Vacinas de DNA/imunologia , Vacinas Sintéticas/imunologia , Adenoviridae/genética , Animais , Antígeno Carcinoembrionário/imunologia , Antígeno HLA-A2/imunologia , Humanos , Imunização , Camundongos , Proteínas de Neoplasias/imunologia , Plasmídeos , Linfócitos T Citotóxicos/imunologia
4.
J Viral Hepat ; 15(11): 782-9, 2008 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-18637068

RESUMO

Dendritic cells (DC) transfected with an adenovirus encoding hepatitis C virus (HCV) NS3 protein (AdNS3) induce potent antiviral immune responses when used to immunize mice. However, in HCV infected patients, controversial results have been reported regarding the functional properties of monocyte-derived DC (MoDC), a cell population commonly used in DC vaccination protocols. Thus, with the aim of future vaccination studies we decided to characterize MoDC from HCV patients transfected with AdNS3 and stimulated with the TLR3 ligand poly(I:C). Phenotypic and functional properties of these cells were compared with those from MoDC obtained from uninfected individuals. PCR analysis showed that HCV RNA was negative in MoDC from patients after the culture period. Also, phenotypic analysis of these cells showed lower expression of CD80, CD86, and CD40, but similar expression of HLA-DR molecules as compared to MoDC from uninfected individuals. Functional assays of MoDC obtained from patients and controls showed a similar ability to activate allogeneic lymphocytes or to produce IL-12 and IL-10, although lower IFN-alpha levels were produced by cells from HCV patients after poly(I:C) stimulation. Moreover, both groups of MoDC induced similar profiles of IFN-gamma and IL-5 after stimulation of allogeneic T-cells. Finally, migration assays did not reveal any difference in their ability to respond to CCL21 chemokine. In conclusion, MoDC from HCV patients are functional after transduction with AdNS3 and stimulation with poly(I:C). These findings suggest that these cells may be useful for therapeutic vaccination in chronic HCV infection.


Assuntos
Células Dendríticas/imunologia , Hepacivirus/imunologia , Hepatite C/imunologia , Fatores Imunológicos/farmacologia , Poli I-C/farmacologia , Receptor 3 Toll-Like/agonistas , Proteínas não Estruturais Virais/imunologia , Adenoviridae/genética , Adulto , Idoso , Antígenos CD/análise , Citocinas/metabolismo , Células Dendríticas/química , Feminino , Vetores Genéticos , Antígenos HLA-DR/análise , Humanos , Masculino , Pessoa de Meia-Idade , Transdução Genética , Proteínas não Estruturais Virais/genética
5.
An Sist Sanit Navar ; 29(1): 77-96, 2006.
Artigo em Espanhol | MEDLINE | ID: mdl-16670731

RESUMO

Pharmacological intervention on the immune system to achieve more intense lymphocyte responses has potential application in tumour immunology and in the treatment of chronic viral diseases. Immunostimulating monoclonal antibodies are defined as a new family of drugs that augment cellular immune responses. They interact as artificial ligands with functional proteins of the immune system, either activating or inhibiting their functions. There are humanized monoclonal antibodies directed to the inhibitory receptor CD152 (CTLA-4) that are being tested in clinical trials with evidence of antitumoural activity. As a drawback, anti-CTLA-4 monoclonal antibodies induce severe autoimmunity reactions in a fraction of the patients. Anti-CD137 monoclonal antibodies have the ability to induce potent immune responses mainly mediated by cytotoxic lymphocytes with the result of frequent complete tumour eradications in mice. Comparative studies in experimental models indicate that the antitumour activity of anti-CD137 monoclonal antibodies is superior to that of anti-CD152. CD137 (4-1BB) is a leukocyte differentiation antigen selectively expressed on the surface of activated T and NK lymphocytes, as well as on dendritic cells. Monoclonal antibodies acting as artificial stimulatory ligands of this receptor (anti-CD137 agonist antibodies) enhance cellular antitumoural and antiviral immunity in a variety of mouse models. Paradoxically, anti-CD137 monoclonal antibodies are therapeutic or preventive in the course of model autoimmune diseases in mice. In light of these experimental results, a number of research groups have humanized antibodies against human CD137 and early clinical trials are about to start.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antígenos CD , Antígenos de Diferenciação , Antineoplásicos/uso terapêutico , Imunoterapia , Neoplasias/terapia , Receptores de Fator de Crescimento Neural , Receptores do Fator de Necrose Tumoral , Viroses/terapia , Animais , Antígenos CD/imunologia , Antígenos de Diferenciação/imunologia , Autoimunidade , Transplante de Medula Óssea/imunologia , Antígeno CTLA-4 , Vacinas Anticâncer/imunologia , Vacinas Anticâncer/uso terapêutico , Doença Crônica , Ensaios Clínicos como Assunto , Ensaios Clínicos Fase II como Assunto , Ensaios Clínicos Fase III como Assunto , Citocinas/imunologia , Humanos , Camundongos , Camundongos Transgênicos , Neoplasias/imunologia , Neoplasias Experimentais/tratamento farmacológico , Neoplasias Experimentais/imunologia , Receptores de Fator de Crescimento Neural/imunologia , Receptores do Fator de Necrose Tumoral/imunologia , Transplante Homólogo , Células Tumorais Cultivadas , Membro 9 da Superfamília de Receptores de Fatores de Necrose Tumoral , Vacinas Virais/imunologia , Vacinas Virais/uso terapêutico , Viroses/imunologia
6.
Curr Cancer Drug Targets ; 4(5): 443-54, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-15320719

RESUMO

Identification of relevant targets for cancer therapy is a major goal in cancer research. In this field, the identification of tumor antigens has opened the possibility of inducing specific anti-tumor immune responses. Among these antigens, carcinoembryonic antigen (CEA) is especially relevant because CEA is expressed in a wide variety of adenocarcinomas such as colon, rectum, pancreas, gastric, breast, etc. The present review focuses on different strategies to induce anti-CEA immune responses. In a first group of strategies, the antigen is administered using viral and bacterial vectors expressing CEA, dendritic cells loaded with CEA protein, or dendritic cells transfected with DNA or RNA expressing CEA. A second group of strategies is based on immunizations with antigenic peptide determinants from CEA, rather than with immunogens containing the whole protein. This has been possible due to the identification of different peptide determinants from CEA, which when presented by MHC class I molecules, are recognized by T cytotoxic lymphocytes. More recently, due to the importance of CD4(+) T cells in the induction of immune responses, T helper peptides presented by MHC class II molecules have also been identified. To overcome the poor immunogenicity of CEA-derived peptide determinants, a common feature of self-antigens, their sequence has been modified to improve binding to MHC molecules or recognition by T cell receptors. Finally, in order to enhance immunization efficacy, some of these strategies have combined the administration of immunogens and cytokines or co-stimulatory molecules. Some of the immunization protocols developed are being tested in clinical trials with promising results. Thus, CEA may prove to be a valuable target antigen for the therapy of a high number of malignancies.


Assuntos
Antígeno Carcinoembrionário/imunologia , Sistemas de Liberação de Medicamentos/métodos , Neoplasias/imunologia , Neoplasias/prevenção & controle , Animais , Antígeno Carcinoembrionário/metabolismo , Humanos
7.
J Acquir Immune Defic Syndr (1988) ; 7(7): 635-40, 1994 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-8207641

RESUMO

Identification of immunodominant T-helper-cell determinants after natural infection is an important step in the design of immunogens for potential use in vaccination. Using cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals and a panel of peptides encompassing the sequence of the regulatory protein vpr from HIV-1, we identified the T-helper determinant QLLFIHFRIGCRHSR, which is active in 37.5% of these individuals. To gain insight on the efficacy of this peptide in helping induce neutralizing antibodies against a B-cell determinant (BD), we synthesized constructs containing B- and T-cell determinants and tested them in BALB/c mice, the highest responders to the T-cell determinant moiety among several strains tested. These immunogens induced antibodies against two chosen B-cell determinants from HIV-1IIIB gp160 (amino acids 310-322 from the V3 loop of gp120 and 736-751 from gp41) that were able to neutralize HIV-1 infection in vitro. The highest neutralization titer against HIV-1IIIB was obtained by immunization with the homopolymer of the construct containing the T-cell epitope from vpr and the B-cell epitope from the V3 loop. We believe that the immunodominant T-cell determinant from vpr is a promising epitope to consider in the design of future peptide vaccines.


Assuntos
Produtos do Gene vpr/imunologia , Anticorpos Anti-HIV/biossíntese , HIV-1/imunologia , Epitopos Imunodominantes/imunologia , Linfócitos T Auxiliares-Indutores/imunologia , Sequência de Aminoácidos , Animais , Especificidade de Anticorpos , Linfócitos B/imunologia , Ensaio de Imunoadsorção Enzimática , Produtos do Gene env/imunologia , Produtos do Gene vpr/química , Proteína gp120 do Envelope de HIV/química , Proteína gp120 do Envelope de HIV/imunologia , Proteína gp160 do Envelope de HIV , Humanos , Soros Imunes/imunologia , Imunização , Epitopos Imunodominantes/química , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos CBA , Dados de Sequência Molecular , Testes de Neutralização , Fragmentos de Peptídeos/química , Fragmentos de Peptídeos/imunologia , Precursores de Proteínas/imunologia , Produtos do Gene vpr do Vírus da Imunodeficiência Humana
8.
J Acquir Immune Defic Syndr (1988) ; 7(2): 129-34, 1994 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-8301524

RESUMO

Phenylalanine-containing peptides from CD4 were synthesized based on chemical similarity with active CD4(81-92)-benzylated peptides. The synthetic peptide FYIFFVEDQKEEDD blocked the binding of gp120 to CD4 and inhibited 50% human immunodeficiency virus (HIV)-induced syncytia formation at a concentration (IC50) of approximately 40-50 microM and HIV p17 expression with an IC50 of approximately 67 microM. The peptide is not toxic to cells in vitro. Moreover, acute toxicity studies carried out in Swiss mice showed the peptide to be nontoxic at a dose of 2,000 mg/kg. This phenylalanine-substituted CD4 peptide may prove to be useful in the treatment of AIDS.


Assuntos
HIV-1/efeitos dos fármacos , Peptídeos/farmacologia , Fenilalanina/química , Proteínas Virais , Sequência de Aminoácidos , Animais , Ligação Competitiva , Antígenos CD4/metabolismo , Linhagem Celular , Ensaio de Imunoadsorção Enzimática , Produtos do Gene gag/biossíntese , Produtos do Gene gag/efeitos dos fármacos , Células Gigantes/microbiologia , Antígenos HIV/biossíntese , Antígenos HIV/efeitos dos fármacos , Proteína gp120 do Envelope de HIV/metabolismo , HIV-1/fisiologia , Camundongos , Dados de Sequência Molecular , Peptídeos/síntese química , Peptídeos/química , Peptídeos/toxicidade , Proteínas Recombinantes/metabolismo , Solubilidade , Produtos do Gene gag do Vírus da Imunodeficiência Humana
9.
Cancer Gene Ther ; 6(6): 514-22, 1999.
Artigo em Inglês | MEDLINE | ID: mdl-10608348

RESUMO

Interleukin-12 (IL-12) has been shown to possess potent immunoregulatory and antitumoral effects. We have evaluated the anti-oncogenic potential and the mechanisms of the antitumoral effect of in vivo adenovirus-mediated transfer of IL-12 gene in a murine model of colon cancer. AdCMVIL-12 was constructed to permit coordinated production of p40 and p35 subunits of IL-12 gene to obtain the maximum IL-12 bioactivity. Infection of murine colon cancer CT-26 cells in vitro with AdCMVIL-12 resulted in the production of high levels of IL-12. In vivo gene therapy of colon cancer nodules by intratumoral injection of AdCMVIL-12 induced a local increase in IL-12 and interferon-gamma levels and a complete regression of the tumor in 26 of 34 (76%) mice. Tumor disappeared between days 7 and 10 after vector administration. The antitumoral effect was mediated by CD8+ T cells and was associated with the generation of cytotoxic T lymphocytes against colon cancer cells. Animals that eliminated the tumor were protected against a second administration of neoplastic cells. Treatment with AdCMVIL-12 of one tumor nodule also caused regression of established tumors at distant sites. These data demonstrate that AdCMVIL-12 is a useful therapeutic tool for established colon cancer in mice and should be considered for application in humans.


Assuntos
Adenoviridae/genética , Neoplasias do Colo/terapia , Terapia Genética , Interleucina-12/genética , Animais , Linhagem Celular , Neoplasias do Colo/imunologia , Feminino , Vetores Genéticos , Humanos , Injeções Intralesionais , Interferon gama/genética , Camundongos , Camundongos Endogâmicos BALB C , Linfócitos T Citotóxicos/imunologia
10.
AIDS Res Hum Retroviruses ; 12(18): 1671-9, 1996 Dec 10.
Artigo em Inglês | MEDLINE | ID: mdl-8959242

RESUMO

Production of cross-reactive antibodies recognizing the V3 loop--that is, the principal neutralizing determinant (PND)--of various HIV-1 isolates is an important challenge in the development of passive immunotherapy or vaccinations against AIDS. We have produced two types of antibodies to the V3 domain of HIV-1: (1) antibodies against the HIV-1 MN laboratory strain generated in rabbits and (2) antibodies targeted to the HIV-1 LAI laboratory strain induced in chimpanzees. These antibodies were shown to be specific for HIV-1 subtype B. The cross-reactivity of these antibodies has been evaluated against a large panel of peptides representing different parts of the V3 loop. Seventy-five peptides, referred to as clinical peptides, were synthesized according to HIV-1 sequences recovered from PMBCs of 27 patients followed in three Parisian hospitals. Thirteen V3 peptides derived from 4 HIV-1 laboratory strains (MN, LAI, SF2, and RF) were also included in the study. The results show that both the amino-terminal and central parts of the V3 loop are immunogenic. The rabbit antibodies against the amino-terminal end of the PND proved to be highly cross-reactive against the clinical peptides. The anti-gp160 antibodies induced in one chimpanzee recognized a significant proportion of the panel of V3 clinical sequences. These antibodies cross-reacted mainly with the apex of the V3 loop. These data give some additional indications on the immunogenicity of the V3 loop and further demonstrate that extensive cross-reactivity of anti-V3 antibodies can be obtained on field HIV-1 isolates despite the high variability of the V3 loop amino acid sequence.


Assuntos
Anticorpos Anti-HIV/imunologia , Proteína gp120 do Envelope de HIV/imunologia , Proteína gp160 do Envelope de HIV/imunologia , Infecções por HIV/virologia , HIV-1/imunologia , Fragmentos de Peptídeos/imunologia , Animais , Infecções por HIV/imunologia , HIV-1/isolamento & purificação , Humanos , Pan troglodytes , Coelhos , Proteínas Recombinantes de Fusão/imunologia
11.
AIDS Res Hum Retroviruses ; 12(11): 1023-30, 1996 Jul 20.
Artigo em Inglês | MEDLINE | ID: mdl-8827218

RESUMO

Phenylalanine-containing peptides from CD4 were synthesized on the basis of chemical similarity with active CD4(81-92)-benzylated peptides. Systematic replacement of amino acids of these peptides bearing the benzyl group by phenylalanine, afforded several peptides that were able to block the binding of gp120 to CD4 and to inhibit HIV-induced syncytium formation. These experiments showed that substitution of residues 81 and 85 by phenylalanine was the most important for activity. Following optimization of the length of phenylalanine-substituted peptides it was found that FYICFVED and FYICFVEDE were the most active. Their IC50 for the inhibition of syncytium formation was around 1.2-1.6 microM. This activity is at least 30 times higher than that of the parent peptide FYIFFVEDQKEEDD previously reported (Lasarte et al., J Acquir Immune Defic Syndr 1994;7:129-134). Binding competition experiments with two different anti-peptide antisera recognizing the V3 region of gp120 and FYICFVEDE, show that the active peptides bind to V3 or to a sterically near region of V3. None of the active peptides was toxic to cells in vitro. The enhanced activity and simplicity of these new phenylalanine-substituted CD4 peptides might be a good starting point for the development of mimotopes of potential use for the treatment of AIDS.


Assuntos
Síndrome da Imunodeficiência Adquirida/prevenção & controle , Antivirais/farmacologia , Antígenos CD4/farmacologia , HIV-1/patogenicidade , Oligopeptídeos/farmacologia , Fragmentos de Peptídeos/farmacologia , Fenilalanina , Antivirais/química , Antígenos CD4/química , Fusão Celular/efeitos dos fármacos , Linhagem Celular , Ensaio de Imunoadsorção Enzimática , Células Gigantes/virologia , Humanos , Técnicas In Vitro , Oligopeptídeos/química , Fragmentos de Peptídeos/química , Relação Estrutura-Atividade
12.
AIDS Res Hum Retroviruses ; 12(6): 519-25, 1996 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-8679307

RESUMO

The objective of the present study was to identify p24 antigenic domains recognized during natural human immunodeficiency virus type 1 (HIV-1) infection, the determination of the major epitopes of p24 having significant applications for both the improvement of diagnostic approaches and the development of vaccines. Reactivity of 20 HIV-1-infected patients and 8 HIV-1-negative patients was analyzed using an enzyme-linked immunosorbent assay (ELISA) developed with 45 overlapping synthetic pentadecapeptides, spanning amino acids 133 to 363 of HIV-1 p55gag precursor. Two peptides covering aa 178-192 and 288-302 of p55 were recognized by 40 and 45% of HIV-1 antibody-positive human samples, respectively. A peptide covering aa 272-322 of p55 was synthesized and recognized by most human sera in indirect ELISA. However, inhibition assays indicated that this sequence does not contain all of the immunodominant domains of p24 since it was not sufficient to block binding of human sera to whole p24. A three-dimensional model of p24 derived from the Mengovirus VP2 suggests that the two distant sequences recognized by human sera containing antibodies to HIV-1 could possibly be a part of a conformational epitope built up by two loops corresponding to aa 183-186 and 289-292.


Assuntos
Linfócitos B/imunologia , Proteína do Núcleo p24 do HIV/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , Sequência de Aminoácidos , Ensaio de Imunoadsorção Enzimática , Epitopos , HIV-1/química , Humanos , Modelos Moleculares , Dados de Sequência Molecular , Peptídeos/síntese química , Peptídeos/imunologia
13.
J Hum Lact ; 13(3): 209-13, 1997 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9341413

RESUMO

In order to determine the effect of feeding glucose water on breastfeeding newborns, we randomly distributed 180 normal newborns into two groups: a glucose water group (GW), fed 5% glucose solution during the first 3 days of life in addition to being breastfed; and an exclusively breastfed nonglucose water group (NGW). The following data were evaluated: weight at 6, 12, 24, 48, and 72 hours of life; temperature during the first 72 hours of life; serum glucose level at 6, 12, 24, and 48 hours; total duration of breastfeeding and age at introduction of infant formulas. In the NGW, there was a greater weight loss at 48 hours but not at 72 hours, temperatures higher than 37.5 degrees C were more frequent, and the mean serum glucose levels at 6, 12, and 24 hours were lower. This group also had more serum glucose level determinations under 2.2 mmol/l (40 mg/dL). However, no infants exhibited hypoglycemic symptoms. Infants in the GW received twice as many formulas during the first month and had a shorter duration of any breastfeeding. Our results suggest that the suppression of feedings with glucose water in the first days of life increases the probability of successful breastfeeding. However, infants who do not receive glucose water in the first few days of life may require greater supervision and close monitoring of blood glucose and body temperature, particularly in the first 24 hours of life.


Assuntos
Glicemia , Temperatura Corporal , Peso Corporal , Aleitamento Materno , Glucose/administração & dosagem , Recém-Nascido/fisiologia , Adulto , Feminino , Humanos , Masculino , Estudos Prospectivos , Soluções , Fatores de Tempo , Redução de Peso
14.
Rev Esp Cardiol ; 43(6): 410-2, 1990.
Artigo em Espanhol | MEDLINE | ID: mdl-2236788

RESUMO

Three cases are presented of patent uncomplicated ductus arteriosus in children, with short systolic murmur, in which the noninvasive diagnosis could not be possible without the echo-Doppler help. Although are cases with small shunts and hemodynamically well tolerated, its diagnosis and surgical treatment are essential in order to prevent the risk of bacterial endocarditis of those patients.


Assuntos
Permeabilidade do Canal Arterial/cirurgia , Criança , Pré-Escolar , Permeabilidade do Canal Arterial/diagnóstico por imagem , Ecocardiografia Doppler , Feminino , Humanos , Masculino
15.
Farmaco ; 54(4): 255-64, 1999 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-10384720

RESUMO

A set of new pyrimido[5,4-b]indole derivatives that are structurally related to some non-nucleside HIV-1 reverse transcriptase inhibitors were synthesized and biologically evaluated for their activity as inhibitors of wild and mutant HIV-1 RT types in an 'in vitro' recombinant HIV-1 RT screening assay, as well as anti-infectives in HLT4lacZ-1IIIB cells. Preliminary structure-activity relationships suggest that activity is promoted by simultaneous substitution in positions 2 and 4, especially when chains of alkyldiamine type are present, and by electron-releasing substituents (methoxy) in positions 7 and 8. The inactivity or the very low activity of title derivatives does not suggest interest in AIDS therapy.


Assuntos
Fármacos Anti-HIV/síntese química , HIV-1/efeitos dos fármacos , Indóis/síntese química , Inibidores da Transcriptase Reversa/síntese química , Fármacos Anti-HIV/química , Fármacos Anti-HIV/farmacologia , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Avaliação Pré-Clínica de Medicamentos , Humanos , Indóis/química , Indóis/farmacologia , Inibidores da Transcriptase Reversa/química , Inibidores da Transcriptase Reversa/farmacologia , Relação Estrutura-Atividade
16.
Vaccine ; 29(41): 7130-5, 2011 Sep 22.
Artigo em Inglês | MEDLINE | ID: mdl-21651945

RESUMO

Adjuvant research is being oriented to TLR-agonists, but complement activation has been relatively unexplored. In previous studies it was demonstrated that poly(methyl vinyl ether-co-maleic anhydride) nanoparticles (PVMA NPs) used as adjuvant differentially activate dendritic cells through toll like receptors (TLR) stimulation, however, a high dose of these NPs was used. Now, we demonstrated a dose-response effect, with a concentration as low as 20µg/mL able to stimulate TLR2 and TLR4 transfected dendritic cells. In addition, we investigated whether PVMA NPs are able to exploit also the immunomodulatory benefits of complement activation. Results indicated that the hydroxylated surface of these NPs highly activated the complement cascade, as measured by adsorption studies and a complement fixation bioassay. Stable binding of C3b to NPs was confirmed as indicated by lability to SDS treatment after washing resistance. Complement consumption was confirmed as the lytic capacity of complement exposed to NPs was abolished against antibody-sensitized sheep erythrocytes, with a minimal inhibitory concentration of 50µg NPs, equivalent to a surface of 1cm(2). On the contrary, nanoparticles prepared with poly(lactic-co-glycolic acid) (PLGA), used as a reference, did not consume complement at a concentration ≥3mg NPs (≥40cm(2)). Complement consumption was inhibited when PVMA NPs were cross-linked with diamino groups (1,3-diaminopropane), indicating the role of hydroxyl groups as responsible of the phenomenon. These results favour a model whereby PVMA NPs adjuvant activate complement on site to attract immature antigen presenting cells that are activated through TLR2 and TLR4.


Assuntos
Adjuvantes Imunológicos/metabolismo , Imunidade Inata , Maleatos/metabolismo , Nanopartículas/química , Polietilenos/metabolismo , Receptores Toll-Like/agonistas , Ativação do Complemento , Complemento C3b/metabolismo , Células Dendríticas/imunologia , Ligação Proteica
17.
Clin Vaccine Immunol ; 17(9): 1356-62, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20631332

RESUMO

The mechanisms that underlie the potent Th1-adjuvant capacity of poly(methyl vinyl ether-co-maleic anhydride) nanoparticles (NPs) were investigated. Traditionally, polymer NPs have been considered delivery systems that promote a closer interaction between antigen and antigen-presenting cells (APCs). Our results revealed that poly(anhydride) NPs also act as agonists of various Toll-like receptors (TLRs) (TLR2, -4, and -5), triggering a Th1-profile cytokine release (gamma interferon [IFN-gamma], 478 pg/ml versus 39.6 pg/ml from negative control; interleukin-12 [IL-12], 40 pg/ml versus 7.2 pg/ml from negative control) and, after incubation with dendritic cells, inducing a 2.5- to 3.5-fold increase of CD54 and CD86 costimulatory molecule expression. Furthermore, in vivo studies suggest that NPs actively elicit a CD8(+) T-cell response. Immunization with empty NPs resulted in a significant delay in the mean survival date (from day 7 until day 23 postchallenge) and a protection level of 30% after challenge against a lethal dose of Salmonella enterica serovar Enteritidis. Taken together, our results provide a better understanding of how NPs act as active Th1 adjuvants in immunoprophylaxis and immunotherapy through TLR exploitation.


Assuntos
Adjuvantes Imunológicos/farmacologia , Maleatos/farmacologia , Nanopartículas/administração & dosagem , Polietilenos/farmacologia , Células Th1/imunologia , Receptores Toll-Like/agonistas , Receptores Toll-Like/imunologia , Animais , Antígeno B7-2/biossíntese , Linfócitos T CD8-Positivos/imunologia , Células Dendríticas/imunologia , Expressão Gênica , Molécula 1 de Adesão Intercelular/biossíntese , Interferon gama/metabolismo , Interleucina-12/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Salmonella enteritidis/imunologia , Salmonella enteritidis/patogenicidade , Análise de Sobrevida
18.
Vaccine ; 28(32): 5323-31, 2010 Jul 19.
Artigo em Inglês | MEDLINE | ID: mdl-20665977

RESUMO

A therapeutic vaccine against chronic hepatitis B virus (HBV) infection requires the development of a strong and multispecific Th1 cell immune response. Woodchucks chronically infected with the woodchuck hepatitis virus (WHV) closely resemble HBV infection and represent the best animal model for this hepadnavirus-induced disease. Using the BIMAS "HLA Peptide Binding Predictions" program, we have identified and further characterized novel H-2 d-restricted CD8+ epitopes within the WHV core (peptides C#12-21, C#18-32, C#19-27, C#61-69) and surface antigens (peptides preS2#10-18, preS2#27-35, S#76-84, S#133-140 and S#257-265), respectively. These peptides bind to H-2 d with high efficiency and upon immunization of mice with peptide and Freund's adjuvant they induce the development of IFN-gamma producing T cells. More importantly, WHV core peptides C#19-27 and C#61-69 and WHV surface peptides S#133-140 and S#257-265 were also recognized by CD8+ T cells after immunization of mice with DNA/PEI nanoparticles. Direct stimulation of splenocytes obtained from such DNA-immunized mice with peptides C#18-32, S#76-84, and S#257-265 resulted in significant production of IFN-gamma. Thus, we have identified T cell determinants in mice from WHV core and surface antigens that have important value for designing and evaluating an effective vaccine against hepadnavirus infection.


Assuntos
Antígenos de Superfície/imunologia , Epitopos de Linfócito T/imunologia , Antígenos de Hepatite/imunologia , Vírus da Hepatite B da Marmota/imunologia , Proteínas do Core Viral/imunologia , Animais , Linfócitos T CD8-Positivos/imunologia , Linhagem Celular , Mapeamento de Epitopos , Feminino , Antígenos H-2/imunologia , Imunidade Celular , Camundongos , Camundongos Endogâmicos BALB C
19.
J Pathol ; 213(3): 347-55, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17940994

RESUMO

Combination therapy with interferon-alpha (IFNalpha) and ribavirin is the current treatment of choice for hepatitis C virus (HCV) infection. However, an important number of patients fail to respond to this therapeutic strategy. Factors determining IFN responsiveness are not well understood, and assessment of biomarkers that predict the response to IFN therapy in HCV patients is necessary. Several studies show that particular HCV proteins are able to block IFN function through interaction with important IFN-signal mediators, such as signal transducers and activators of transcription (STATs). We performed immunostaining analysis of STATs in liver tissue from IFN-responder vs. non-responder HCV patients in order to compare the expression profile of these proteins between both groups. Tissue arrays of liver biopsies were used to study the expression of STAT1, STAT2, STAT5 and PIAS1 (protein inhibitor of activated STAT1). Robust and higher expression levels of STAT1, STAT2 and STAT5 in liver tissue from HCV patients were found when compared with samples from healthy donors. However, no significant differences were observed between IFN-responder and -non-responder groups, but rather increasing levels of STAT1, STAT2 and STAT5 paralleled the degree of liver injury. Importantly, PIAS1 expression in the nucleus of most hepatocytes in HCV tissue biopsy sections, particularly of non-responder HCV patients, strongly indicated a regulatory effect on STAT1-DNA binding, likely affecting the IFN late signalling. In conclusion, our evidence indicates that intense PIAS1 nuclear staining, widely distributed in hepatocytes of infected livers, could be a good predictive factor of a defective response to IFN treatment, and a biomarker that is easily detectable by immunostaining during standard histopathological liver biopsy analysis.


Assuntos
Antivirais/uso terapêutico , Hepacivirus , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/uso terapêutico , Fígado/química , Proteínas Inibidoras de STAT Ativados/análise , Proteínas Modificadoras Pequenas Relacionadas à Ubiquitina/análise , Adolescente , Adulto , Antivirais/metabolismo , Biomarcadores/análise , Estudos de Casos e Controles , Linhagem Celular Tumoral , Núcleo Celular/química , Feminino , Fibrose , Antígenos da Hepatite C/análise , Hepatite C Crônica/genética , Hepatite C Crônica/metabolismo , Humanos , Imuno-Histoquímica , Interferon-alfa/metabolismo , Fígado/metabolismo , Fígado/patologia , Masculino , Pessoa de Meia-Idade , Proteínas Inibidoras de STAT Ativados/genética , Fator de Transcrição STAT1/análise , Fator de Transcrição STAT1/genética , Fator de Transcrição STAT2/análise , Fator de Transcrição STAT2/genética , Fator de Transcrição STAT5/análise , Fator de Transcrição STAT5/genética , Proteínas Modificadoras Pequenas Relacionadas à Ubiquitina/genética , Resultado do Tratamento , Regulação para Cima
20.
J Viral Hepat ; 13(1): 47-55, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16364082

RESUMO

Successful clearance of hepatitis C virus (HCV) infection has been associated with strong cellular immune responses against viral antigens. However, although the magnitude of these responses is clearly important for viral eradication, more studies are needed to unravel the fine specificity of the protective anti-HCV immunity in infected patients. This was the aim of the present study. Overlapping peptides spanning the sequence of HCV E2 and NS4a proteins were used to stimulate T cells from patients with chronic hepatitis C divided into three groups: naïve patients, patients who exhibited sustained response to interferon (IFN)-alpha therapy and patients who failed to respond to the treatment. Interleukin-2 production by stimulated cells was measured in each case. Patients with sustained response to therapy had stronger responses to E2 peptides than nonresponders, whereas naïve patients demonstrated intermediate reactivity. In the case of NS4a, responses against peptides where similar in all groups of patients. Analysis of the peptides recognized by T cells showed that responses were broad and heterogeneous, and some immunodominant epitopes, preferentially recognized by patients exhibiting sustained response to treatment, were found. These results confirm the role of cellular immune responses in viral clearance, and stress the importance of immunodominant regions within HCV antigens. These viral sequences may represent valuable immunogens for preparation of therapeutic or prophylactic vaccines.


Assuntos
Hepacivirus/imunologia , Hepatite C/imunologia , Linfócitos T/imunologia , Proteínas do Envelope Viral/imunologia , Proteínas não Estruturais Virais/imunologia , Adulto , Idoso , Sequência de Aminoácidos , Feminino , Antígenos HLA-DR/genética , Antígenos HLA-DR/imunologia , Hepacivirus/genética , Hepatite C/virologia , Humanos , Epitopos Imunodominantes/imunologia , Interleucina-2/análise , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Fragmentos de Peptídeos/imunologia , Fragmentos de Peptídeos/farmacologia , RNA Viral/química , RNA Viral/genética , Linfócitos T/efeitos dos fármacos , Linfócitos T/virologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa